Human Norepinephrine Neuron Generation via Staged Stem Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to produce human norepinephrine (NE) neurons from human pluripotent stem cells (hPSCs) at a large scale and in a standardized manner, hindering disease modeling and cell therapy for neurological disorders.
Innovation Solution
A method involving culturing human neuroepithelial cells with hindbrain R1 regional identity in specific concentrations of Activin A and inhibitors of BMP and TGFβ signaling, followed by neural differentiation to generate NE neuron progenitors and mature NE neurons, which express TH and DBH, and can be genetically modified with a GRABNE sensor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional animal models and standard stem cell differentiation protocols are used, then disease modeling can be performed, but the models do not accurately reflect human disease pathology and NE neuron generation from hPSCs cannot be achieved
Solution Approach 1:
The patent applies parameter changes by systematically optimizing culture conditions including Activin A concentration (10-50 ng/mL initially, then 100-250 ng/mL), BMP inhibitor concentration (1-5 μM), and TGFβ inhibitor concentration (1-5 μM) to achieve successful NE neuron differentiation from hPSCs, resolving the contradiction between model accuracy and cellular versatility
Solution Approach 2:
The patent employs preliminary action by pre-differentiating hPSCs into neuroepithelial cells with hindbrain R1 regional identity before inducing NE neuron differentiation, which prepares the cells in advance with the appropriate regional specification needed for authentic human NE neuron generation
2Productivity
If forced expression of NE determinants Phox2b or Phox2a is used in mouse embryonic stem cells, then NE neurons can be generated, but this strategy fails to produce NE neurons from human pluripotent stem cells
Solution Approach 1:
The patent changes the approach from forced gene expression to optimized culture parameters including specific concentrations of Activin A, BMP inhibitors, and TGFβ inhibitors, achieving NE neuron differentiation from hPSCs without transgenic manipulation, thus resolving the species-specific limitation
Solution Approach 2:
The patent replaces the mechanical/genetic intervention approach (forced expression) with a biochemical signaling approach (growth factor and inhibitor treatment), substituting the mechanism of NE neuron induction to achieve cross-species applicability
3Productivity
If large-scale standardized production of NE neurons is implemented, then disease modeling and drug development can be enhanced, but current methods lack the capability to produce NE neurons in a standardized manner
Solution Approach 1:
The patent segments the differentiation process into distinct stages: neuroepithelial cell generation with hindbrain R1 identity, NE neuron progenitor specification, and mature NE neuron differentiation, with optimized parameters for each stage enabling standardized large-scale production
Solution Approach 2:
The patent establishes standardized parameter ranges for each differentiation stage including Activin A concentration (10-50 ng/mL then 100-250 ng/mL), BMP inhibitor (1-5 μM), and TGFβ inhibitor (1-5 μM), creating a reproducible manufacturing protocol
Data Source
AI summary
Methods for obtaining populations of norepinephrine (NE) neuronal progenitor cells and creating enriched populations of NE neurons are provided herein. Also provided herein are methods for obtaining genetically modified NE neurons expressing a NE sensor or a TH-reporter, and methods for using NE neurons obtained according to the methods of this disclosure.